MM-121 is a fully human monoclonal antibody that targets ErbB3.
The Phase 2 study will assess efficacy of MM-121 in combination with paclitaxel as compared to treatment with paclitaxel alone when administered as part of a neoadjuvant treatment regimen.
The company expects to enroll around 200 patients.